Shenlian Biological plans to acquire 237 million yuan worth of Shizhiyuan's equity stake

NightAirdropper · 2026-02-26T19:50:31+00:00

Shenlian Biopharmaceuticals plans to acquire a 51% stake in Yangzhou Shizhiyuan Biotechnology through its wholly-owned subsidiary, becoming a controlling subsidiary and expanding its dual main businesses in innovative pharmaceuticals and animal health. The transaction amount is 237.4418 million yuan, funded by self-owned and self-raised capital. The company's operating income and net profit are on a downward trend, facing multiple risks.

NightAirdropper

2026-02-26 19:50:31

Abstract generation in progress

Radar Finance | Written by Feng Xiuyu | Edited by Li Yihui

On February 24, Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. (Stock Code: 688098) announced that the company plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. through its wholly owned subsidiary, Shanghai Bentiancheng Biopharmaceutical Co., Ltd., via equity transfer and capital increase. After the transaction is completed, Bentiancheng and its concerted parties will hold a total of 51.00% of Shizhiyuan’s equity, making Shizhiyuan a controlling subsidiary of the company, and it will be included in the company’s consolidated financial statements.

Following this acquisition, the company will fully develop its innovative drug business, forming a new pattern of coordinated development between “human medicines” and “animal health.” The transaction involves a total amount of 237.441789 million yuan, funded by self-owned and self-raised funds (including bank acquisition loans).

According to Tianyancha, Shenlian Biopharmaceuticals was established on June 28, 2001, with a registered capital of 410.644 million yuan. The legal representative is Nie Dongsheng, and the registered address is No. 48 Jiangchuan East Road, Minhang District, Shanghai. Its main business includes the research, production, and sales of biological products for animal prevention, treatment, and diagnosis.

Currently, the company’s chairman is Nie Dongsheng, the secretary of the board is Yu Haixia, with 391 employees. The actual controllers are Yang Yufang, Yang Congzhou, Wang Dongliang, and Nie Dongsheng.

The company has three associated companies, including Gansu Shenlan Breeding Co., Ltd., Shanghai Shenrui Lian Biopharmaceuticals Co., Ltd., and Juying Foreign Animal Disease Prevention and Control Taizhou Co., Ltd.

In terms of performance, the company’s operating income for 2022, 2023, and 2024 was 329 million yuan, 301 million yuan, and 303 million yuan, respectively, with year-on-year changes of -8.32%, -8.25%, and 0.64%. Net profit attributable to the parent was 61.0982 million yuan, 31.5187 million yuan, and -44.7401 million yuan, with year-on-year declines of -44.56%, -48.42%, and -241.95%. During the same period, the company’s asset-liability ratio was 6.74%, 5.45%, and 8.27%.

Regarding risks, Tianyancha data shows that the company has 7 internal Tianyan risks, 4 surrounding risks, 30 historical risks, and 70 early warning risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.